For advanced or recurrent esophageal cancer Of combination therapy - docetaxel-cisplatin-5 fluorouracil phase I/II trial
Not Applicable
- Conditions
- Advanced or recurrent esophageal cancer
- Registration Number
- JPRN-UMIN000014625
- Lead Sponsor
- gifu University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Cases with (heart disease, interstitial pneumonitis or pulmonary fibrosis, and cirrhosis of the liver) complications serious. patients with serious infections Patients with edema required Treatment Cases with non-pleural effusion control, ascites Patients with a history of drug hypersensitivity serious. Cases there is a possibility that pregnant women, pregnant and lactating women. Cases is determined participation in the test is difficult and complicated by psychiatric symptoms or psychosis Patients undergoing (oral or intravenous) systemic continuous administration ofsteroid Cases attending physician was deemed inappropriate In carrying out Other, this clinical trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint estimate the optimal dose of docetaxel in combination therapy in CF. consider kind of side effects, the severity. Secondary endpoints To examine the anti-tumor effect and incidence of adverse events.
- Secondary Outcome Measures
Name Time Method